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Objective: Skeletal related events (SREs) are common in patients with bone metastases and lead to
decreased quality of life and functional status. The deﬁnition of an SRE has evolved over the years and
now excludes hypercalcemia of malignancy due to its low incidence. The purpose of this review was to
investigate if advances in bone-targeted therapies have decreased skeletal morbidity rates (SMR)
over time.
Methods: A literature search was conducted in several databases to identify phase III results from bone-
targeted therapy trials from 1980 through September 2011. Graphs were created to document the
trends of the natural log of SMR over the mean time of enrolment for all placebo and intervention arms.
Statistical hypothesis testing was employed to account for confounding factors.
Results: A total of 14 studies were identiﬁed which reported the SMR from phase III trials from 1990 to
2007. A statistically signiﬁcant downward trend was observed in the placebo arms of trials over time; a
similar trend was seen in all intervention arms. In a direct comparison of intervention against placebo
arms, it was found that there was a signiﬁcant decreasing time trend (po0.0001) and a signiﬁcant
departure in SMR from placebo to intervention arms (p¼0.0348). These results were seen even after
accounting for the confounding factors of histology and differences in drugs.
Conclusion: The decrease in SMR over time may not only be a result of advancements with bone
targeted agents, but also due to better management and awareness of events associated with bone
metastases.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metastatic disease in advanced cancer most commonly man-
ifests itself in bone. Of all advanced breast or prostate cancer, 65%
to 75% of patients develop metastases to bone, while in patients
with other solid tumours 30% to 40% of patients will develop bone
metastases [1]. Patients with bone metastases are at a high risk
of developing SREs (such as bone pain requiring analgesics or
palliative radiation therapy, spinal cord compressions (SCC), patho-
logical fractures, hypercalcemia, or a need for surgery), which can
greatly reduce quality of life (QOL) [3]. Retrospective analyses of
several tumour types have demonstrated that patients with bone
metastases who experience an SRE are more likely to experience
subsequent SREs [2]. SREs undermine patients’ functioning, beget
signiﬁcant morbidity, and reduce patients’ survival. As treatment. This is an open access article un
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Chow).intent for patients with advanced cancers shifts from survival to the
preservation of QOL, the principal objective becomes the manage-
ment and prevention of SREs secondary to bone metastases.
‘‘Skeletal-related complications’’ as a quantiﬁable clinical end
point were ﬁrst deﬁned as pathologic fractures, irradiation of or
surgery on bone, spinal cord compression, or hypercalcemia of
malignancy (HCM); they were ﬁrst applied to studies assessing
pamidronate in women with bone metastases from breast can-
cer [3]. In the past, HCM was highly prevalent in breast cancer
patients with bone metastases [3]; but today, it is a condition that
is rarely seen due to a better understanding of the disease and the
frequent use of anti-resorptive therapies. Therefore, in more recent
studies, HCM has been excluded in the standard SRE deﬁnition. This
is appropriate, as comparisons of HCM rates reported in studies
performed in the 1990s show signiﬁcantly lower rates of HCM than
those conducted in the 1970s and 1980s [4]. In a retrospective
analysis of patients with breast cancer from 1975 to 1984 who had
ﬁrst recurrence of disease in the bone, 17% developed hypercalce-
mia [5]. In the placebo arm of a study evaluating the safety of cyclic
pamidronate in breast cancer patients, where study enrolmentder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bone disease was 13%, compared with 6% in the pamidronate
arm [4].
The introduction of bone targeting agents to patients’ treatment
has been shown to be beneﬁcial in preventing SREs and reducing
pain in large phase III trials. Bone targeted therapies have been
found to prolong the time to ﬁrst SRE and reduce the rate of
SREs [6]. The introduction of new anti-resorptive therapies into
clinical practice, such as the nitrogen-containing IV bisphosphonate
pamidronate early in the 1990s, zoledronic acid from 2000, and
receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor
denosumab in 2010 is accompanied by increased disease state
awareness. Consequently, general standards of care in the skeletal
health of cancer patients have improved.
Nonetheless, SREs remain a common problem for patients with
bone metastases from advanced cancer. As such, curtailing SREs
will have beneﬁts for the healthcare system in terms of reduced
patient morbidity and lower healthcare costs [7]. The skeletal
morbidity rate (SMR) is deﬁned as the ratio of the number of SREs
for each subject divided by the subject’s time at risk in years. For
example, if a study follows 1000 patients for one year and among
those 1000 patients 350 SREs occur, then the SMR value would be
0.35 SREs/year. If multiple events are experienced within a year
these values are included within the ratio.
This review aims to investigate how developments in bone
targeted therapies have affected the incidence of SMRs over time.
A trend analysis was performed to examine the SMR from the
placebo arms of randomized controlled trials (RCTs) over time,
and also the trend in the SMR values from the intervention arms
of those RCTs over the same time period.2. Methods
A literature search was conducted in MEDLINE (OvidSP) (1980
through September 2011), EMBASE (OvidSP) (1980 through Septem-
ber 2011), and Cochrane Central Register of Controlled Trials (OvidSP)
(September 2011) to identify phase III results from bisphosphonate
and other bone-targeted therapy trials. The following medical subject
headings and text words were used: ‘‘exp neoplasms’’, ‘‘cancer’’,
‘‘carcinoma’’, ‘‘tumor’’, ‘‘malignan:’’, ‘‘bone neoplasms/sc’’ (secondary),
‘‘bone metast:’’, ‘‘osseous metast:’’, ‘‘bone pain’’, combined with
‘‘exp diphosphonates’’, ‘‘bisphosphonate’’, ‘‘exp alendronate’’, ‘‘alen-
dronate’’, ‘‘alendronic acid’’, ‘‘exp clodronic acid’’, ‘‘clodronic acid’’,
‘‘clodronate’’, ‘‘dichloromethylene’’, ‘‘exp etidronic acid’’, ‘‘etidronic
acid’’, ‘‘etidronate’’, ‘‘exp ibandronate’’, ‘‘ibandronate’’, ‘‘ibandronic
acid’’, ‘‘pamidronate’’, ‘‘aredia’’, ‘‘exp zoledronic acid’’, ‘‘zoledronic
acid’’, ‘‘zolendronate’’, ‘‘zometa’’, and ‘‘denosumab’’. Those terms were
then combined with the search terms for the following publication
types and study designs: practice guidelines, systematic reviews,
meta-analyses, reviews, randomized controlled trials, and controlled
clinical trials. The literature search was not restricted by language.
Studies were limited to phase III and IV trials involving patients with
solid tumours, excluding trials in patients with multiple myeloma.
Articles reporting the same population data were excluded.
Results of the search were independently sorted for potential
inclusion by 6 coauthors. This process identiﬁed 20 eligible
studies. The number of SREs that occurred was gathered for all
interventions and placebo arms of studies. This included radiation
therapy, pathological fractures, spinal cord compression, surgical
intervention and hypercalcemia. The articles were further reﬁned,
selecting only those that reported SMR. SMR values were the most
consistently quoted outcome measure after SRE, in 14 of the 20
identiﬁed studies. The SMR was identiﬁed to be the primary
outcome of interest in this study as it standardizes the rate of
skeletal-related events over a time period, typically one year,where pure numerical events would unequally weigh trials to
those with the longest follow-up or largest cohort.
As we were not privy to the median year of enrolment, for all
selected studies, the mean enrolment year ([start of enrol-
mentþend of enrolment]/2) was calculated. If these dates were
unavailable, the corresponding authors or sponsoring companies
were contacted. When all methods to gather this information were
exhausted, for studies that did not report their enrolment period,
the average of the mean enrolment year for the same intervention
drug reported in literature was used. Here, an assumption was
made that intervention drugs tend to be tested over approximately
the same years. To normalize the distribution of SMR, natural log-
transformation was applied. Graphs were created depicting SMR
(log-scale) as a function of the year of enrolment for placebo arms
and treatment arms. Due to the different enrolment numbers in
each study, the SMR log-values were weighed accordingly (also
known as weighted least squares). Weighted linear regression
modiﬁed the standard linear regression model (minimizing the
square of the error between predicted value Y^ i and the actual
value Yi) to min
Pm
i ¼ 1 WiðYiY^ iÞ2, where Wi is the weighted value
for each study (known as number of patients per study).These
weighted linear regression models over time were constructed and
p-values less than 0.05 were considered as statistically signiﬁcance.
Negative coefﬁcients of time (slope) indicate that the average SMR
(log-scale) is decreasing over enrolment year. The interaction term
for the slopes of placebo versus intervention patients was calcu-
lated as well. We also conducted the above models with accounting
for histology and/or drug as confounding factors due to hetero-
geneous studies. Histology was treated as a categorical variable
with different primary cancer sites including breast, bladder, lung
(other solid tumors), prostate, and renal cell carcinoma. For inter-
vention treatment, different drug mechanism were accounted for,
these included denosumab, ibandronate, pamidronate, and zole-
dronic acid. R2 was calculated for each model, with higher values of
the R2 demonstrating better model ﬁtting.
This process was repeated while considering histology as a
confounding factor for both placebo and intervention arms. For
patients treated with intervention, the different drugs used were
also considered as a confounding factor. All analysis was con-
ducted by Statistical Analysis Software (SAS version 9.2 for
Windows).3. Results
3.1. Analysis of SMR
A total of 14 studies were identiﬁed which reported SMR and
the dates of enrolment (Table 1). The majority (7/14) included
patients with breast cancer, three of the remaining involved
patients with prostate cancer, two with renal cell carcinoma
and a single study for each of primary bladder cancer and lung
or other solid tumors. Enrolment periods for included studies
ranged 17 years, from 1990 to 2007. Most studies identiﬁed
compared zoledronic acid to placebo.
An overall downward trend was observed in the placebo arms
of all studies using the natural log model of SMR (Fig. 1). In the
early 1990s, SMRs ranging between 3.0 and 4.0 were not uncom-
mon. After approximately a decade and a half, SMRs were reduced
to around a single event per year. This trend was found to be
statistically signiﬁcant with a p-value of 0.0021 with a Pearson’s
correlation coefﬁcient of 0.63.
During the same time period, statistically signiﬁcant decreases
in SMR were observed in all intervention arms included with a
p-value less than 0.0001 with a R2 of 0.64 (Fig. 2). At its peak in
the early 1990s, SMRs ranged between 2.0 and 3.0. From the
Fig. 1. Skeletal morbidity rates (SMR) over time of placebo arms in phase III trials
with weighted linear regression model.
Fig. 2. SMR rates over time of all intervention arms in phase III trials with
weighted linear regression model.
Table 1
Studies reporting SMR values ordered by publication date.
Author Pub
year
Enrol
start
Enrol
end
Primary
cancer
Treatment SMR
Arm 1 Arm 2 Arm 3 Arm
1
Arm
2
Arm
3
Theriault [3] 1999 1990 1995 Breast Pamidronate Placebo NA 2.40 3.80 NA
Lipton [4] 2000 1990 1996 Breast Pamidronate Placebo NA 2.40 3.70 NA
Saad [20] 2002 1998 2001 Prostate Zoledronic acid
(4 mg)
Zoledronic acid
(8 mg)
Placebo 0.80 1.06 1.49
Rosen [21] 2004 1998 1999 Breast Zoledronic acid Zoledronic acid Pamidronate 0.98 1.06 1.55
Body [22] 2003 NR NR Breast Ibandronate Ibandronate Placebo 1.31 1.48 1.19
Lipton [23,24] 2003 NR NR Renal Cell Zoledronic acid Zoledronic acid Placebo 2.68 1.67 3.38
Rosen [25] 2004 NR NR Lung, solid
tumours
Zoledronic acid
(4 mg)
Zoledronic acid
(8 mg)
Placebo 2.24 1.55 2.52
Tripathy [26] 2004 1996 2000 Breast Ibandronate (20 mg) Ibandronate (50 mg) Placebo 0.97 0.98 1.20
Saad BJU (Renal Subgroup) [27] 2006 NR NR Renal Cell Zoledronic acid Placebo NA 2.58 3.13 NA
Saad (Clinical Prostate Cancer)
[2]
2007 1998 2001 Prostate Zoledronic acid Placebo NA 0.42 0.88 NA
Saad BJU (Prostate Subgroup)
[28]
2005 1998 2001 Prostate Zoledronic acid Placebo NA 0.77 1.47 NA
Kohno [29] 2005 2000 20030 Breast Zoledronic acid Placebo 0.63 1.10 NA
Stopeck [7] 2010 2006 2007 Breast Denosumab Zoledronic acid NA 0.45 0.58 NA
Zaghloul [30] 2010 2005 2007 Bladder Zoledronic acid Placebo NA 0.85 2.05 NA
Fig. 3. SMR rates over time of zoledronic acid treatment arms in phase III trials
with weighted linear regression model.
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than one event per year. Improvements in SMR were seen in
zoledronic acid arms compared to earlier intervention arms. Whenlooking solely at studies reporting results of zoledronic acid trials
relatively stable SMR values were seen across the time period 1990–
2007 (Fig. 3). This trend across 14 zoledronic intervention arms
indicates that stable beneﬁts were incurred, but with a non-
signiﬁcant decreasing trend (p¼0.0855; R2¼0.23). In zoledronic
acid trials, SMRs were consistently around 1.0 events/year (events/
year ranged from 0.42 to 2.68). Following relatively stable SMRs
across all zoledronic acid trials, a further decrease in SMR is seen in
the breast cancer denosumab trial, where a SMR value of 0.45 was
found [8].
In a direct comparison of intervention arms against placebo
arms (Table 2), it was found that there was a signiﬁcant decreas-
ing time trend (po0.0001) and a signiﬁcant departure in SMR
from placebo in intervention arms (p¼0.0348) (Fig. 4). The non-
signiﬁcant interaction term (p¼0.51) indicates that the decreas-
ing slope found in placebo or intervention patients are similar.
The R2 for the model was also calculated to be 0.73.
Overall, SMR rates in intervention arms are lower than placebo
arms. Further data analyzing factors that could have confounded
SRE and SMR values were tabulated. This included primary
cancer, primary end point, study duration, percentage of patients
Table 2
Weighted linear regression model of natural log of SMR over time in patients treated with Intervention or with Placebo.
Parameter Coefﬁcient Standard Error p-value
Before accounting for confounding factors
Intercept 215.7770 29.4006 o0.0001
TRT (1¼Interv., 0¼PCB) 0.3487 0.1579 0.0348
Year 0.1077 0.0147 o0.0001
After accounting for confounding factors
Intercept 224.2987 19.5678 o0.0001
TRT (1¼Interv., 0¼PCB) 0.3318 0.1065 0.0043
Year 0.1116 0.0098 o0.0001
Histology o0.0001
Bladder vs. renal cell carcinoma 0.0220 0.6446 0.9730
Breast vs. renal cell carcinoma 0.8485 0.3244 0.0144
Lung (other solid tumors) vs. renal cell carcinoma 0.2156 0.3446 0.5369
Prostate vs. renal cell carcinoma 1.1920 0.3376 0.0015
TRT indicates treatment group of intervention or placebo (1 or 0).
Interv.: Intervention.
PCB: Placebo.
Year
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
Lo
g_
S
M
R
-2
-1
0
1
2
Intervention
Placebo
Fig. 4. Comparison of SMR trends for all intervention arms (solid circle) against all
placebo arms (open triangle).
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(Table 3).
3.2. Analysis of SMR accounting for confounding factors
In patients treated with placebo, after accounting for the
confounding factor of histology a signiﬁcant average decrease in
SMR over time is seen. The trend was found to still be statistically
signiﬁcant (p¼0.0011) with a Pearson’s correlation coefﬁcient of
0.9040. The confounding factor of histology was also found to be
insigniﬁcant (p¼0.056).The R2 for the model was also calculated
to be 0.90.
Similarly, when the confounding factors of histology and drug
mechanisms were accounted for as confounders, the results
indicate there is a signiﬁcant average SMR decrease over the year
in patients receiving interventions (p¼0.0014).The R2 for the
model was also calculated to be 0.93. The confounding factor of
histology was statistically signiﬁcant (p¼0.0006), but the drug
mechanism was not (p¼0.0698).
While previously the trend for zoledronic acid trials was not
found to be statistically signiﬁcant, after accounting for differences
in histology, the results indicate there is a signiﬁcant average SMR
decrease over time in patients receiving zoledronic acid (p¼0.0211).
The Pearson’s correlation coefﬁcient was found to be 0.8224 for the
model. When analyzing the time trend for zoledronic acid trials, theconfounding factor of histology was signiﬁcant (p¼0.0114). The R2
for the model was also calculated to be 0.82.
Finally, after accounting for histology, all patients exhibit sig-
niﬁcant decreases in SMR over time (po0.0001). There was also a
signiﬁcant difference between patients treated with intervention or
with placebo (p¼0.0043) (Table 2). The negative coefﬁcient of
treatment (0.3318) indicated patients treated with placebo have
higher SMRs compared to patients within intervention arms. The
confounding factor of histology is signiﬁcant (po0.0001). The R2 for
the model was also calculated to be 0.90. Therefore, after adjusting
for confounding histology we still ﬁnd a signiﬁcant decreasing time
trend and signiﬁcant treatment effect from intervention.4. Discussion
This analysis ﬁnds a reduction in the occurrence of SMRs over
the time frame from 1990 to 2007. SMRs of both placebo and
intervention arms decreased over time, but remained relatively
constant in patients receiving the third generation bisphospho-
nate zoledronic acid. In studies with the most recent bone
targeted agent denosumab, an additional relative reduction in
SMR of 22% was seen in comparison to zoledronic acid [7]. This
suggests not only that newer bisphosphonates and bone-targeted
agents are improving outcomes for patients, but management
strategies and awareness of such disease is improving at the
same time.
As is evident by analysis of SMR, improvements are being
made in the treatment of bone metastases. This is likely by
reducing osteoclast-mediated bone resorption and subsequently
normalizing calcium levels. Bisphosphonates have been devel-
oped through three generations, with current research focusing
on the monoclonal antibody denosumab. Although few direct
comparisons were found, second generation bisphosphonates
were shown to decrease the risk of SRE similarly to ﬁrst genera-
tion bisphosphonates but with longer lasting pain relief [3]. This
can be exempliﬁed by how signiﬁcantly better bone-pain scores
were reported with 90 mg intravenous pamidronate compared
with a 1600 mg/day oral clodronate regimen, in patients with
bone metastases from a variety of primary sites [8]. In a number
of later trials, zoledronic acid has been shown to decrease the
number of SREs in comparison to earlier bisphosphonates. As
Rosen et al. found, long-term treatment in lung cancer patients
and other patients with solid tumor using zoledronic acid (4 mg)
has shown an additional 20% reduction in the risk of skeletal
complications in comparison to treatment by pamidronate [9].
Table 3
Study design of studies including SMR values or pure SRE numbers.
Authors Pub
year
Total
(ITTN)
Patient
selection
Primary
end point
Arm 1 Arm 2 Arm 3 Study
duration
% on
chemo
% prev
SRE
Dearnaley [31] 2009 819 Prostate Symptomatic BPFS Clodronate Placebo NA 5 years NR NR NA NR NR NA
Lipton [23] 2004 74 Renal cell
carcinoma
Proportion of SRE Zoledronic
acid
Placebo NA 9
months
NR NR NA 82 95 NA
Saad [32] 2004 122 Prostate Proportion with SRE Zoledronic
acid (4 mg)
Placebo Zoledronic
acid (8/4 mg)
15
months
NR NR NR 82 82 NR
Saad [2] 2007 422 Prostate Proportion with SRE Zoledronic
acid
Placebo NA 15
months
NR NR NA 30.8 37.5 NA
Tripathy [26] 2005 312 Breast SMR Ibandronate Placebo NA 96
weeks
NR NR NA NR NR NA
Rosen [33] 2001 1648 Breast/MM Non-inferiority,
proportion of SRE
Zoledronic
acid
Pamidronate NA 13
months
81 82 NA 68 68 NA
Rosen [21] 2004 1648 Breast/
MM—long
term
Proportion on SRE Zoledronic
acid
Pamidronate NA 25
months
NR NR NA NR NR NA
Fizazi [10] 2011 1904 Prostate Time to ﬁrst on-
study SRE
Denosumab Zoledronic
acid
NA NR 14 14 NA 24 24 NA
Hortobagyi [34] 1996 382 Breast Proportion with SRE Pamidronate Placebo NA 12
months
100 100 NA 38 47 NA
Kohno [29] 2005 228 Breast SRE rate Zoledeonic
acid
Placebo NA 12
months
26 34 NA 34 42 NA
Lipton [4] 2000 754 Breast SMR Pamidronate Placebo NA 24
months
8.7 11.7 NA NR NR NA
Lipton [24] 2003 74 Renal cell
carcinoma
Proportion of SRE Zoledronic
acid
Zoledronic
acid
Placebo 9
months
NR NR NR 82 81 95
Rosen [25] 2004 773 Lung, other
solid tumours
Proportion with SRE Zoledronic
acid (4 mg)
Zoledronic
Acid (8 mg)
Placebo 9
months
82 80 80 65 68 73
Rosen [9] 2003 1130 Breast Proportion with SRE Zoledronic
acid
Zoledronic
Acid
Pamidronate 12
months
47 47 47 38 43 37
Saad [20] 2002 643 Prostate Proportion with SRE Zoledronic
acid (4 mg)
Zoledronic
Acid (8 mg)
Placebo 15
months
NR NR NR 30.8 32.1 37.5
Saad [28] 2005 422 Prostate Proportion with SRE Zoledronic
acid
Placebo NA 15
months
NR NR NA 31% 37.5 NA
Saad BJU (RENAL
SUBGROUP) [27]
2006 46 Renal cell
carcinoma
Proportion with SRE Zoledronic
acid
Placebo NA 15
months
NR NR NA 81 95 NA
Saad BJU (PROSTATE
SUBGROUP) [28]
2005 422 Prostate Proportion with SRE Zoledronic
acid
Placebo NA 15
months
NR NR NA 30.8 37.5 NA
Saad [35] 2010 422 Prostate Proportion with SRE Zoledronic
acid
Placebo NA 15
months
NR NR NA 30.8 37.5 NA
Small [36] 2003 378 Prostate Reduction of pain,
proportion on SRE
Pamidronate Placebo NA 27
weeks
40 43 NA 52 51 NA
Stopeck [7] 2010 2049 Breast Time to ﬁrst trial SRE Denosumab Zoledronic
acid
NA NR 40 40 NA 37 37 NA
Theriault[3] 1999 372 Breast SMR Pamidronate Placebo NA 96
weeks
NR NR NA NR NR NA
Tripathy [26] 2004 435 Breast SMR Ibandronate
20 mg
Ibandronate
50 mg
Placebo 96
weeks
34.7 39.2 32.2 NR NR NR
Zaghloul [30] 2010 40 Bladder Proportion of SRE Zoledronic
acid
Placebo NA 6
months
NR NR NA NR NR NA
ITTN: intent to treat population.
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cantly delayed the time to ﬁrst trial SRE and reduced the risk of
subsequent SREs when compared to zoledronic acid in breast
cancer patients. In a separate trial, Fizazi et al. [10] accrued
similar ﬁndings with prostate cancer patients, with the median
time to ﬁrst SRE being 20.7 months compared to 17.1 monthly, for
denosumab and zoledronic acid, respectively.
The exhibited efﬁcacies of bone targeting treatments, in phase III
clinical trials, suggest signiﬁcant progress in delaying skeletal-
related events, with improvements having been seen in the direct
comparisons between generations of drugs. These ﬁndings also lend
clear support to the utility of bone targeted agents in comparison to
treatment with placebo. An analysis of phase III trials attests to
zoledronic acid’s increased beneﬁts over previous generations of
bisphosphonates. For this reason, it is the only bisphosphonate that
has received US and European approval for treatment of bone
metastases, independent of primary tumor type [6].
As treatment intent for patients with advanced cancer is to
improve quality of life, it is important to consider the potentialburden of debilitating SREs. Previous studies have found that after
SREs, signiﬁcant decline not limited to physical well-being, but
also emotional and functional well-being is seen [11]. In addition,
negative ﬁnancial impact is also observed in patients who have an
SRE; the estimated SRE-related cost per patient is USD 11,979 in
one’s lifetime [11]. This cost, in addition to subsequent supportive
care, totals approximately USD 28,000 per patient [12]. Of this,
radiotherapy accounted for the greatest proportion of cost (61%)
by SRE type, followed by bone surgery (21%) [11]. It is important
to note that approximately 80% of the costs of treatment of SREs
are incurred within 2 months of the ﬁrst SRE-related claim.
Therefore, proper management with bone targeted therapies are
highly relevant in this population, and our study adds to growing
evidence supporting the importance of therapy to help prevent or
delay bone resorption.
The fact that the SMR decreased in placebo arms over time hints
that management of patients with bone metastases and awareness
of the risk of SREs has improved. It is possible that, over time, due to
improved understanding of bone biology, recognition of early
M. Poon et al. / Journal of Bone Oncology 1 (2012) 74–80 79symptoms of bone metastases, initiation of an improving selection
of anti-cancer therapeutic options, early introduction of treatment
and better skeletal care education, SRE incidence has declined and
will continue do so over time. In the past decade, improvements
have been made to allow for early detection of spinal cord
compression; magnetic resonance imaging (MRI) has been demon-
strated to be the most reliable method, with 95% diagnostic accuracy
[13]. Prophylactic stabilization and the use of prophylactic surgery
for metastatic lesions have also been shown to provide a distinct
survival advantage and are associated with relatively low perio-
perative risk [14]. These improvements in management could be
reﬂected in the SMR decrease in the placebo arms over time. In a
study of immediate or delayed treatment with zoledronic acid,
immediate-start zoledronic acid was found to increase the preven-
tion of bone loss, a factor that can contribute to SREs such as pain
and fractures [15]. These results demonstrate the effect of timely
treatment that could similarly be revealed in SMR data. A similar
effect can be seen with denosumab studies, where better hazard
ratio is seen among patients with no prior SRE, compared to those
with prior SREs [16]; this indicates increased prevention ability with
timely treatment. No data was collected with respect to the date of
diagnosis or metastasis of patients, making it difﬁcult to determine
the state of the disease at which the patients were referred. But,
perhaps this amelioration in management strategies in the latter
time period, concurrent with increased bisphosphonate efﬁcacy,
could elucidate our SMR trend.
It is also possible that primary therapies directed at the tumour
might have had an effect on the time trend results. While the
primary therapy practice has not changed; the proportion of
patients receiving it has. For example, since the introduction of
docetaxel in prostate cancer, across the studies, up to 82% of patients
were on chemotherapy. In comparison, in a contemporary trial with
the RANKL inhibitor denosumab performed by Fizazi et al. [10], the
beneﬁts of bone targeted agents were seen while one third of
patients received docetaxel. It can also be seen that in the later
studies examined 40% of breast cancer patients had been placed on
chemotherapy [7]. While data on whether patients were on che-
motherapy was limited, these discrepancies could account for the
SMR trend. The proportion of patients on chemotherapy may also
reﬂect a change in the need for primary therapy or changes in
patient options. This change in chemotherapy use could account for
the trends in SMR rates in the placebo arms of the studies.
The potential improvement in management of patients can be
evidenced by a paper comparing baseline symptom severity over
two time frames by Khan et al.[17]. Baseline edmonton symptom
assessment system (ESAS) scores reported by patients seen from
2006 to 2009 were found to exhibit signiﬁcant improvement for
most items, as compared to values taken from 1999 to 2002. The
largest magnitude of difference in symptom severity was found in
depression, with a median score for depression of 0.0 from 2006
to 2009 compared to 2.0 from 1999 to 2002 [17]. Similar
decreases were also seen in pain, fatigue and sense of wellbeing.
A probable cause for these items may be the increased referral to
palliative care. An increased trend in palliative care has been
exhibited and may signiﬁcantly reduce the symptom severity of
patients at risk of bone metastases, especially when coupled with
the aforementioned early incorporation in disease trajectory [18].
It is for this reason, palliative treatment has gained increasing
support as a vital component of comprehensive cancer care, with
ASCO resolving to induct palliative care as routine by 2020 [19].
The heterogeneity in reporting SRE outcomes limits the compar-
ison of studies using bone targeted agents. More phase III data are
available than what have been presented herein (Table 3). Unfortu-
nately, due to varying endpoint deﬁnitions in the literature, we are
unable to include additional studies which may have strengthened
our ﬁndings. Heterogeneity may also arise from the differences inhistology between primary breast, prostate, myeloma, lung, renal and
bladder cancers, however our results indicate that regardless of
history or the different drug mechanisms SMR values are decreasing
signiﬁcantly. Our ﬁndings may further be confounded by the varia-
bility of the included studies themselves. Certain studies reported
extended follow-up periods, while others were published after a
predetermined endpoint. Depending on the time frame in which data
were captured, this may inﬂate or deﬂate true SMR rates. As observed
in the data presented, studies on patients with primary renal cell
carcinoma generally reported greater SMRs than other cancers, which
may have inﬂuenced our ﬁndings.
Nevertheless, we have included a selection of articles spanning
over a decade and a half which clearly demonstrates SMR time
trends across generations of bone modifying agents and their
respective effects on bone modeling and tumor burden. Our study
reﬂects the trends of the SREs reported in clinical trials, which
may not be the same as in daily practice. We encourage clinicians
and researchers to report the latter for comparison.
In conclusion, improvements in SMRs of both placebo arms
and intervention arms were seen over the years accounting for
confounding factors of histology and differences in drugs used.
This suggests that newer bisphosphonates and bone-targeted
therapies are improving outcomes for patients, adding to the
growing evidence in support of bone-targeted agent use. As well,
these ﬁndings lend clear support to how improvements in
management strategies and awareness of bone disease in meta-
static cancer parallels the advances made in bone targeting
treatments, as evidenced by SMR.Acknowledgements
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